Quarterly report pursuant to Section 13 or 15(d)

License Agreement for HT-100 (Details Narrative)

v3.19.3
License Agreement for HT-100 (Details Narrative) - License Agreement [Member]
Aug. 29, 2019
USD ($)
Consideration amount paid $ 10,000
Achieving Certain Future Development and Regulatory Milestones Related to Drug [Member] | Maximum [Member]  
Consideration amount paid $ 12,000,000